SCHEMBL299979

SCHEMBL299979

CCOc1cc(CN2CCC3(CC2)CC(=O)N(c2ccc(C(=O)O)cc2)C3)cc(OCC)c1-c1ccc(F)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
SSTR5 P35346 20/20 1.00
KCNH2 Q12809 3/20 1.00
PTGDR Q13258 2/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25313810 0.94 SSTR5 (0.89) SSTR5KCNH2PTGDR
SCHEMBL289639 0.94 SSTR5 (0.89) SSTR5KCNH2PTGDR
SCHEMBL10111531 0.93 SSTR5 (0.88) SSTR5KCNH2PTGDR
SCHEMBL10111911 0.93 SSTR5 (0.88) SSTR5KCNH2PTGDR
SCHEMBL289895 0.93 SSTR5 (0.88) SSTR5KCNH2PTGDR
SCHEMBL25315155 0.93 SSTR5 (0.86) SSTR5KCNH2PTGDR
SCHEMBL13076435 0.93 SSTR5 (0.86) SSTR5KCNH2PTGDR
SCHEMBL10111292 0.93 SSTR5 (0.86) SSTR5KCNH2PTGDR
SCHEMBL25900407 0.93 SSTR5 (0.86) SSTR5KCNH2PTGDR
SCHEMBL10111477 0.93 SSTR5 (0.86) SSTR5KCNH2PTGDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250066359-A1 SOMATOSTATIN RECEPTOR SUBTYPE 5 ANTAGONISTS, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2025-02-27 US disclosed
CN-119320397-A SSTR5-TGR5 double-effect compound, and preparation method, pharmaceutical composition and application thereof 中国科学院上海药物研究所 2025-01-17 CN disclosed
CN-119019309-A GPR40 agonism-SSTR 5 antagonistic double-effect compound, preparation method and application thereof 南昌大学 2024-11-26 CN disclosed
WO-2023125486-A1 SOMATOSTATIN RECEPTOR SUBTYPE 5 ANTAGONISTS, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF 中国科学院上海药物研究所 2023-07-06 WO disclosed
CN-116354961-A Somatostatin receptor 5 antagonist, and pharmaceutical composition and application thereof 中国科学院上海药物研究所 2023-06-30 CN disclosed
CN-115215787-A Somatostatin receptor 5 antagonists and uses thereof 中国科学院上海药物研究所 2022-10-21 CN disclosed
EP-2427465-A1 SUBSTITUTED SPIROCYCLIC AMINES USEFUL AS ANTIDIABETIC COMPOUNDS Merck Sharp & Dohme Corp. (US) 2012-03-14 EP disclosed
US-20120041012-A1 SUBSTITUTED SPIROCYCLIC AMINES USEFUL AS ANTIDIABETIC COMPOUNDS MERCK SHARP & DOHME CORP. 2012-02-16 US disclosed
US-20120041012-A1 SUBSTITUTED SPIROCYCLIC AMINES USEFUL AS ANTIDIABETIC COMPOUNDS MERCK SHARP & DOHME CORP. 2012-02-16 US disclosed
WO-2010129729-A1 SUBSTITUTED SPIROCYCLIC AMINES USEFUL AS ANTIDIABETIC COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2010-11-11 WO disclosed
WO-2010129729-A1 SUBSTITUTED SPIROCYCLIC AMINES USEFUL AS ANTIDIABETIC COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120041012-A1 SUBSTITUTED SPIROCYCLIC AMINES USEFUL AS ANTIDIABETIC COMPOUNDS SSTR5, SSTR2, GPR119 SSTR5 1/4885KCNH2 1142/4885PTGDR 209/4885
US-20250066359-A1 SOMATOSTATIN RECEPTOR SUBTYPE 5 ANTAGONISTS, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF SSTR5, SSTR2, SSTR3 SSTR5 1/4885KCNH2 2363/4885PTGDR 133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.